Korea / Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster?
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown…
Ahn-Gook Pharmaceutical Co. Ltd
Last updated: 25.02.2015
Ahn-Gook Pharmaceutical Co. Ltd has developed and supplied outstanding medicines for the last 45 years, dedicated to developing “advanced pharmaceutical products for health and happiness of the mankind.” As a result of this sustainable effort and growth Ahn-Gook has achieved KOSDAQ enlistment and transparent management as a recognized pharmaceutical developer. Ahn-Gook has set a new vision to realize “new world-class medicine and global marketing by 2020.” In the 21st century, only companies with core technology and key manpower survive. Therefore, Ahn-Gook is accumulating core technology to develop new world-class medicine and fostering key manpower for developing and marketing our new medicines.
Contact details
993-75 Daerim-2-dong Yeongdeungpo-gu, Seoul
TEL +82 2 3289 4200
Related
Joong Myung Cho – Chairman & CEO, CrystalGenomics, South Korea
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Young-Shik Cho – Chairman, SD Biosensor
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their…
Precision Medicine / Reclaiming Asia's Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome…
Jeong-Sun Seo – Chairman, Macrogen & President, KoreaBIO
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO),…
Sangrae Cho – CEO, Gencurix
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae…
Yeul-Hong Kim – Director, K-MASTER, South Korea
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data…
M&A / Korean Celltrion Makes First Big Global Move with Acquisition of Takeda APAC Assets
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
SCM Lifescience / A Global Approach to Korean Regenerative Medicine
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in…
Jisoo Pae – CEO, Genome & Company
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr…
Rare Diseases / Korean Corestem Targets US Market for Ground-Breaking ALS Treatment
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea,…
Kyung Suk Kim – CEO, Corestem
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic…
